Abstract The ability of patients with hematologic malignancies (HM) to develop an effective humoral immune response after COVID-19 is unknown. A prospective study was performed to monitor the immune response to SARS-CoV-2 of patients with follicular lymphoma (FL). diffuse large B-cell lymphoma (DLBCL). chronic lymphoproliferative disorders (CLD). https://foldlyers.shop/product-category/coupler/